<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02179528</url>
  </required_header>
  <id_info>
    <org_study_id>BJCHDTC001</org_study_id>
    <nct_id>NCT02179528</nct_id>
  </id_info>
  <brief_title>Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)</brief_title>
  <official_title>Phase 2 Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <brief_summary>
    <textblock>
      Patients with extensive-stage small cell lung cancer receive six cycles of&#xD;
      chemotherapy(etoposide plus platinum) as first-line treatment,who achieve Complete&#xD;
      Response(CR)/Partial Response(PR) will accept small doses of etoposide as maintenance&#xD;
      treatment. The objective of this study is to evaluate the progression free survival,overall&#xD;
      survival,objective response rate,disease control rate and safety of etoposide as maintenance&#xD;
      therapy. Based on previous studies on maintenance therapy in small cell lung cancer,the&#xD;
      hypothesis of this study is maintenance therapy using etoposide may improve progression free&#xD;
      survival,overall survival for selected patients. The investigators will use the peripheral&#xD;
      blood to assess circulating tumor cell and cell-free DNA,which may help us to screen a&#xD;
      subgroup of patients with better response to etoposide maintenance therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Small Cell Lung Cancer Extensive Stage</condition>
  <arm_group>
    <arm_group_label>etoposide,maintenance therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>etoposide,25mg qd d1-20，repeat every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>blank control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>blank control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <arm_group_label>etoposide,maintenance therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathological diagnosis of small cell lung cancer&#xD;
&#xD;
          -  Extensive stage according to American Veteran Staging System&#xD;
&#xD;
          -  At least one measurable lesion according to Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST )1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) scores for performance status of 0 to 2&#xD;
&#xD;
          -  Age≥18 years&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Consent form according with Guideline for Good Clinical Practice of the International&#xD;
             Conference on Harmonisation (ICH-GCP)guidelines&#xD;
&#xD;
          -  The expected survival≥2 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pathological diagnosis of mixed small cell lung cancer&#xD;
&#xD;
          -  Limited stage according to American Veteran Staging System&#xD;
&#xD;
          -  Other preexisting or existing malignant tumors,not including non-melanoma skin cancer&#xD;
             with effective treatment,cervical cancer in situ or tumor response has been 3 years&#xD;
             which is considered cured by the investigator&#xD;
&#xD;
          -  Known pre-existing interstitial lung disease&#xD;
&#xD;
          -  Pre-existing or uncontrolled gastrointestinal disease which may affect drug absorption&#xD;
             or worsen existing disease believed by the investigator&#xD;
&#xD;
          -  Any other medical history or coexisting disease that may affect compliance of patients&#xD;
             or the assessment of safety and effectiveness of the drug believed by the investigator&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Active phase of hepatitis B virus infection,Active phase of hepatitis C virus&#xD;
             infection or known HIV carriers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Wang, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Wang, doctor</last_name>
    <phone>0086 108816456</phone>
    <email>zlhuxi@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100042</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jie Wang, doctor</last_name>
      <phone>0086 1088196456</phone>
      <email>zlhuxi@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2014</study_first_posted>
  <last_update_submitted>September 10, 2014</last_update_submitted>
  <last_update_submitted_qc>September 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Jie Wang</investigator_full_name>
    <investigator_title>Chief of thoracic cancer department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

